⚡ Fast checkout · ships in 24–48h Pay Pay VISA

Sold per vial RetaNord Retatrutide 10 mg research peptide vial

Flagship · BestsellerIncretin receptor agonist

Retatrutide

Triple agonist of the GLP-1, GIP and glucagon receptors · 10 mg lyophilised · lot-specific CoA

Triple agonist (GLP-1 / GIP / glucagon) · 39-residue peptide

The “next-generation” GLP-1 — a triple agonist (GLP-1 / GIP / glucagon) linked to the largest weight changes in recent trials.

€89.9510 mg · LyophilizedIn stock

Plain, unbranded packaging. No product names, no logos — nothing on the outside indicating what is inside. Tracked to a DPD Locker or your address.

Guaranteed delivery. If your order doesn't reach you, we ship it again free — lost, damaged or stolen.

Buy more, save moreup to −25% per vial · free EU shipping over €200

1×€89.95

2×€80.96/ea−10%

Most popular3×€76.46/ea−15%

5×€71.96/ea−20%

Best value10×€67.46/ea−25%

Buy 10 → save €224.87 vs single vials, with free EU shipping. Larger or reseller order? Wholesale pricing →

Order How we test

Order within — for dispatch on the next working day.

Purity 99%+ HPLC

Shipping Free over €200

Documentation CoA included

Need to reconstitute it? Add bacteriostatic water (3 mL · €5) at checkout — the diluent every lyophilised peptide needs.Add →

For laboratory and in vitro research use only. Not for human or veterinary use, and not for use in diagnostic procedures.

Stocked & shipped in the EUDispatched in 24–48hFree EU shipping over €200No customs lotteryCoA in every box

ClassSynthetic peptide (triple incretin/glucagon agonist)

Half-life~6 days

CategoryIncretin receptor agonist

Price€89.95

View Certificate of Analysis

About Retatrutide

Retatrutide is a synthetic 39-amino-acid peptide engineered as a triple agonist of three metabolic receptors: GLP-1, GIP and glucagon. The molecule incorporates non-natural amino-acid modifications and a C20 fatty-diacid attachment that extends its plasma half-life — a structural strategy shared with semaglutide and tirzepatide. It is one of the most-studied incretin-class compounds in recent metabolic and obesity research.

RetaNord supplies retatrutide as a 10 mg lyophilized powder verified at 99%+ identity purity by HPLC, with identity confirmed by mass spectrometry. A lot-specific Certificate of Analysis is included with every order.

What it's known for

Retatrutide is best known for weight loss and metabolism. Here is what it is most associated with. (Still investigational; supplied for laboratory research use only.)

Trial endpoint

Body-weight change was the primary endpoint reported in its published Phase-2 trial.

Triple agonist

Hits three receptors — GLP-1, GIP and glucagon — hence 'next generation'.

Metabolism

Associated with blood-sugar and metabolic regulation.

Still in trials

NB: retatrutide is investigational and not an approved medicine.

Ozempic vs Retatrutide

One receptor versus the triple-agonist researchers call the next generation.

Ozempicsemaglutide

RetatrutideRetaNord

Receptors hit

1GLP-1

3GLP-1 · GIP · glucagon

Type

Single agonist

Triple agonist

Weight change in trials

≈15%

≈24%

Dosing

1× / week

“Next generation”

✗

✓

Read the full Ozempic vs Retatrutide breakdown →

Phase-2 trial data: retatrutide ≈24.2% body weight at 48 weeks (NEJM 2023); semaglutide ≈14.9% at 68 weeks (STEP-1). Separate studies, different populations and durations. Ozempic® is a registered trademark of Novo Nordisk A/S; RetaNord is not affiliated with or endorsed by Novo Nordisk. Supplied for laboratory research use only.

Proof, not hype.

Every claim on this page is backed by documentation you can check — not testimonials.

99%+

Identity purity, HPLC-verified — printed on the Certificate of Analysis in every box.

Independent methods per lot: HPLC for purity, mass spectrometry for identity.

≈24%

Mean body-weight change reported in phase-2 retatrutide trials (NEJM 2023) — the published context, for reference only.

24–48h

EU-stocked and dispatched, with lot-matched paperwork and tracked shipping.

See Certificates of Analysis

How it works

Retatrutide acts on three metabolic receptors at once — GLP-1, GIP and glucagon (a 'triple agonist'). GLP-1 and GIP reduce appetite and slow stomach emptying; glucagon influences energy expenditure. The combined effect across the three axes is why it is associated with strong weight loss.

What the evidence shows

Retatrutide has completed a Phase-2 trial programme, reported in the New England Journal of Medicine (2023); Phase-3 trials are underway. It is NOT yet an approved medicine — unlike semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro), which are already on the market.

An educational summary, not a treatment claim or medical advice.

Safety data from published trials

Third-party literature — not medical adviceSummarised from published clinical research on the investigational compound. RetaNord products are supplied for laboratory and in vitro research use only; not for human or veterinary use.

In the Phase-2 trial published in the New England Journal of Medicine (2023), the adverse events investigators reported most frequently were gastrointestinal — nausea, vomiting, diarrhoea and constipation — and were described as dose-dependent and generally mild to moderate.

Retatrutide is investigational. It has not been evaluated or approved by the European Medicines Agency, the FDA or any other regulatory authority, and no long-term safety profile has been established.

Specifications

Every RetaNord lot is independently verified before dispatch. The figures below describe the product class; exact lot-specific results are documented on the Certificate of Analysis included with your order.

Compound class	Synthetic peptide (triple incretin/glucagon agonist)
CAS number	2381089-83-2
Molecular weight	≈ 4731 g/mol
Identity purity	99%+ (HPLC)
Identity confirmation	Mass spectrometry
Presentation	10 mg lyophilized powder
Physical form	Sterile-filtered, freeze-dried
Storage	2-8°C; -20°C long term
Documentation	Lot-specific Certificate of Analysis

Documentation & quality

Retatrutide passes the same five-stage RetaNord quality process applied to every product: HPLC potency analysis, mass-spectrometry identity and purity confirmation, pH and stability validation, sterility and endotoxin (LAL) testing, and QC batch-consistency verification.

A lot-specific Certificate of Analysis ships with every order. The lot number printed on your vial matches the lot ID on the document, so the material on your bench can always be checked against the data on file.

References & research

Selected peer-reviewed literature on Retatrutide (via PubMed), provided for educational context. A reference does not imply a clinical claim for RetaNord products.

Retatrutide — questions

Why do you only sell 10 mg?

On purpose. Once a lyophilised peptide is reconstituted it slowly degrades, so a larger vial would lose potency before it could be used up — you'd be drawing weakened material by the end. A 10 mg vial is sized so a reconstituted batch stays within its usable window from the first draw to the last. It's a deliberate quality choice, not a limitation.

What makes retatrutide unusual?

Retatrutide is a triple agonist — it activates three receptors (GLP-1, GIP and glucagon) in a single molecule. Most incretin-class peptides target one or two of those receptors; the triple-agonist combination is the focus of newer metabolic research.

How is retatrutide supplied?

As a 10 mg lyophilized powder in a sealed vial, with a lot-specific Certificate of Analysis. It should be reconstituted only in an appropriate laboratory setting following your own validated protocol.

Peptide Kits

A separate range of fifteen research peptides — supplied as sealed 10- or 30-vial kits, not per vial like Retatrutide.

Browse peptide kits →

Documented peptides, on your bench tomorrow.

Every RetaNord order ships within 24–48 hours with full analytical documentation in the box.

Order

Support

Contact us any time

A person answers every message — the same day, seven days a week.

Message us on Telegram Email us

€89.95Order